Copyright © 2021. Inderes Oyj. All rights reserved.

Faron Pharmaceuticals

Analyytikko

Viimeisin video

Sisäpiirin kaupat

Nettovaikuttavuus

Muut analyysit
16.5.
2022

Faron announced earlier today that the company’s New Drug (IND) application to initiate the phase I/II BEXMAB study with lead candidate Bexmarilimab has been approved by both the US Food and Drug Administration (FDA) and the Finnish Medicines Agency

Tiedotteet
16.5.
2022

Faron Pharmaceuticals Ltd.

("Faron" or "Company")

Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate

Tiedotteet
12.5.
2022

Faron Pharmaceuticals Ltd.

("Faron" or "Company")

Ex Vivo Data Presented at EHA2022 Congress Suggest Critical Role for Clever-1 in

Tiedotteet
9.5.
2022

Faron Pharmaceuticals Ltd.

("Faron" or "Company")

Molecular Cancer Therapeutics Publishes Research on the Nonclinical Characterization of Bexmarilimab

Press release, May 9, 2022 at 02:00 AM (EDT) / 07:00 AM (BST) / 09:00 AM (EEST)

Tiedotteet
4.5.
2022

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Grant of options

Company announcement, 04 May 2022 at 1:15 PM (EEST) 11:15 AM (BST) / 6:15 AM (EDT)

Tiedotteet
22.4.
2022

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

Board Changes

Company announcement, April 22, 2022 at 15:01 PM (EEST) / 13:01 PM (BST) / 8:01 AM (EDT) 

Tiedotteet
22.4.
2022

Faron Pharmaceuticals Ltd ("Faron" or the "Company")

Results of the Annual General Meeting and Decisions of the Board of Directors

Company announcement, April 22, 2022 at 15:00 PM (EEST) / 13:00 PM (BST) /  8:00 AM (EDT) 

TURKU, FINLAND- The annual general meeting ("AGM") of Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON) took place at Event Venue Eliel inHelsinki, Finlandtoday, 22 April 2022.

inderesTV
22.4.
2022

Faronin toimitusjohtajan Markku Jalkasen katsaus vuoden 2022 yhtiökokouksessa.

Muut analyysit
19.4.
2022

Redeye initiates coverage of Faron Pharmaceuticals, a Finnish biotech company focused on developing next-generation immunotherapy, its three promising pipeline projects provides multiple inflection points ahead.

Faron Pharmaceuticals

ipo